AstraZeneca’s oral relaxin agonist delivered encouraging phase 2b results in chronic heart failure, improving measures of cardiac function across two patient groups.
The phase 2b data from the Luminara trial, presented during the European Society of Cardiology Congress in Munich, Germany, included 235 patients with heart failure and a left ventricular ejection fraction (LVEF) of 35% or less, or moderately to severely reduced heart pumping function, and 140 patients with heart failure and an LVEF of 41% to 55%.
The study was a double-blind, dose-ranging trial in which patients were randomized to receive placebo or the oral relaxin agonist AZD5462 at 20 mg, 80 mg or 360 mg once daily. The primary endpoint for patients with LVEF of 35% or less was the change from baseline in the end-systolic volume index, a measure of the amount of blood left in the heart’s ventricle at the end of a contraction. The primary endpoint in patients with LVEF of 41% to 55% was the change from baseline in systemic vascular resistance index, a measure of the resistance the heart must push against to pump blood through the body.
The researchers found that in the moderate-to-severe heart failure cohort with LVEF of 35% or less, the lowest dose of AZD5462 decreased the end-systolic volume index by 5.4 mL/m2 compared with baseline. In the LVEF 41% to 55% cohort at 24 weeks, AZD5462 reduced systemic vascular resistance index by 19%, 21% and 15% at doses of 20 mg, 80 mg and 360 mg, respectively.
Relaxin is a pregnancy hormone heavily produced by the placenta to help relax joints and prepare the body for childbirth. The hormone also has a role in heart failure by helping dilate blood vessels and reduce fluid congestion, which is why AstraZeneca has been working on developing a cardiovascular disease pipeline for more than 10 years, Mina Makar, SVP of global cardiovascular, renal and metabolism at AstraZeneca, explained to Fierce.
AZD5462 is an oral, small-molecule selective agonist of the relaxin family peptide receptor 1 (RXFP1). It mimics the role of relaxin, aiming to bind to the RXFP1 receptor to trigger downstream signaling, reduce systemic vascular resistance and reverse cardiac remodeling in heart disease.
Targeting this pathway has been challenging. Earlier this year, AstraZeneca canned its long-acting relaxin-2 analog, AZD3427, from the pipeline after underwhelming efficacy in a phase 2 trial. Eli Lilly had a similar RXFP1-targeting relaxin analog, volenrelaxin, that it axed from the pipeline around the same time.
Finding the right dose that properly balances safety and efficacy has been a tough task in developing a noninjectable candidate, Makar admitted.
“We believe we’ve identified the right dose that allows us to get the right benefit within heart failure,” Makar told Fierce.
While it’s “always going to be about the outcomes eventually,” AstraZeneca feels “this is at least a good sign that we have a small molecule that delivers early signals of positive effect in heart failure, particularly in the reduced ejection fraction patient, with the type of tolerability you would want to see.”
Facts Only
* AstraZeneca conducted a phase 2b trial called Luminara.
* The trial took place in Munich, Germany, and results were presented at the European Society of Cardiology Congress.
* 235 patients had heart failure with a left ventricular ejection fraction (LVEF) of 35% or less.
* 140 patients had heart failure with an LVEF of 41% to 55%.
* Participants received either a placebo or AZD5462 at daily doses of 20 mg, 80 mg, or 360 mg.
* AZD5462 is an oral, small-molecule selective agonist of the relaxin family peptide receptor 1 (RXFP1).
* In the LVEF ≤35% group, the 20 mg dose decreased end-systolic volume index by 5.4 mL/m2 from baseline.
* In the LVEF 41%-55% group at 24 weeks, systemic vascular resistance index was reduced by 19% (20 mg), 21% (80 mg), and 15% (360 mg).
* AstraZeneca previously discontinued a relaxin-2 analog, AZD3427.
* Eli Lilly previously discontinued a relaxin analog called volenrelaxin.
Executive Summary
AstraZeneca is developing AZD5462, an oral small-molecule drug designed to mimic the hormone relaxin to treat chronic heart failure. By targeting the RXFP1 receptor, the drug aims to reduce systemic vascular resistance and reverse cardiac remodeling. Recent phase 2b data from the Luminara trial indicate positive early signals across two distinct patient cohorts: those with moderately to severely reduced heart pumping function (LVEF ≤35%) and those with mildly reduced function (LVEF 41% to 55%).
The trial demonstrated a reduction in end-systolic volume index for the most severe group at the lowest dose, and a reduction in systemic vascular resistance for the milder group across all tested doses. These results follow a period of volatility in relaxin-targeting research, during which both AstraZeneca and Eli Lilly abandoned previous analog candidates due to insufficient efficacy. While current results are encouraging regarding tolerability and early cardiac markers, definitive success depends on future data regarding long-term patient outcomes.
Full Take
The strongest version of this narrative is that AstraZeneca has successfully pivoted from unstable analogs to a viable small-molecule oral agonist, overcoming a hurdle that previously stymied both them and Eli Lilly. The data points to a precise "Goldilocks" dosing window where efficacy is achieved without compromising tolerability.
However, a pattern scan reveals an Authority Game. The central claim—that the company has "identified the right dose"—is supported exclusively by the internal assertions of AstraZeneca's SVP of global cardiovascular, renal and metabolism. The "positive signals" are based on surrogate endpoints (volume index and vascular resistance) rather than hard clinical outcomes like mortality or hospitalization rates. The narrative frames these surrogate markers as a "good sign," effectively substituting biomarker movement for clinical proof of benefit.
Patterns detected: ARC-0045 Authority Game
The driving paradigm is the pharmaceutical "pipeline" logic: the need to signal progress to stakeholders after previous failures. This echoes a common industry pattern where early-phase biomarker success is presented as a proxy for eventual therapeutic victory to maintain momentum. For the patient, the benefit is a potential shift from injectable to oral therapy, but the cost is the inherent uncertainty of whether these physiological changes actually translate into longer or better lives.
If this were a coordinated influence campaign, the playbook would involve using technical jargon (RXFP1, LVEF) to create a veneer of certainty while relying on a single corporate executive to validate the "breakthrough" status of a drug that has not yet proven it saves lives. The content aligns partially with this by relying on corporate say-so for the most critical conclusion.
Bridge Questions:
1. How strongly do changes in end-systolic volume index and systemic vascular resistance correlate with actual survival rates in heart failure patients?
2. What specific safety data was observed at the 360 mg dose that might explain the dip in efficacy compared to the 80 mg dose?
3. What independent, third-party validation exists for the "tolerability" mentioned by the company?
Counterstrike Scan: The content matches the pattern of a corporate press summary; it is clean of malicious influence but relies on a vendor-centric evidence loop.
Sentinel — Human
The text reads like standard, well-vetted science journalism reporting on a specific clinical trial result, supported by relevant context and expert commentary.